- BPC-157 dominates the gut-healing conversation on the strength of preclinical rodent studies, but no controlled human trials have been indexed, and the female-specific record is thinner still.
- KPV, a C-terminal alpha-MSH tripeptide, has been studied for anti-inflammatory signaling in gut and skin models, with translation to female physiology an open research question.
- Neither gut peptide has pregnancy, lactation, or hormonal-interaction data, and any BPC-157 dosing figure circulating online is extrapolated from male-animal studies.
Few compounds have outrun their evidence the way BPC-157 has. It is everywhere in the gut-healing conversation, and its research file is almost entirely preclinical rodents. Its usual companion in that conversation, KPV, is a genuinely interesting anti-inflammatory fragment with a similarly preclinical record. For a catalog built around sex-disaggregated evidence, the gut category is a clean example of popular interest running far ahead of what has actually been studied, especially in women.
BPC-157: real mechanism data, no human trials
BPC-157 is a synthetic pentadecapeptide, a 15-amino-acid chain derived from a protein sequence found in gastric juice. In preclinical models it has been studied for its relationship to angiogenesis, growth-factor signaling, and the nitric-oxide system, most often in rodent tissue-injury protocols involving tendon, muscle, and gut. That mechanism work is real, and it is why the compound keeps reappearing as a reference material. The honest headline is what is missing: controlled human trials have not been indexed, so the gap between the popular narrative and the clinical record is wide.
KPV: a defined anti-inflammatory fragment
KPV is a tripeptide of lysine, proline, and valine, corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). It is often studied as a way to isolate the anti-inflammatory portion of that larger melanocortin peptide without its pigmentary activity. In preclinical and in-vitro gut-epithelial, dermal, and immune-cell models it has been studied for its relationship to inflammatory-response signaling, including modulation of NF-kappaB activity and pro-inflammatory cytokine pathways. Its minimal structure narrows the studied mechanism to a defined fragment, which is scientifically tidy, but it remains preclinical, and whether it translates to female physiology is an open question.
You will find BPC-157 dosing numbers all over the internet. They trace back to animal studies, and for a compound with no indexed human trials there is no established human dose. This site does not publish personal dosing and reports dose information only as it appears in the research literature. Nothing here is medical advice.
The female record, or the absence of one
For BPC-157, every female-evidence field returns unstudied. No studies examine menstrual cycle interactions. There is no estrogen, thyroid, or contraceptive interaction data, no perimenopausal or menopausal data, and no pregnancy or lactation safety data, where again absence of harm data is not evidence of safety. Even within the preclinical work, the small number of studies using female animals reported no sex-stratified outcomes. KPV's record is similarly preclinical, with translation to women framed as an open research question rather than an established finding.
The gut category makes the site's core point almost too neatly: the mechanism data can be substantial while the female data is essentially absent, and one does not stand in for the other. That is why the question of how many studies included women is the one worth asking first. For the full evidence states and derived grades, see the BPC-157 and KPV profiles.